Sai Parenterals Redirects ₹83.83 Crore IPO Proceeds To Saicriti Acquisition

Other Costs Squeeze Margins PAT at Rs 7.9 Cr in Q1 FY27 (consolidated), +459.9% YoY. Revenue at Rs 179 Cr in Q1 FY27 (consolidated), +435.1% YoY. EBITDA at Rs 27.3 Cr, +360.6% YoY. EBITDA margin at 15.3% vs 17.7%; other expenses grew 959% vs revenue growth of 435%. Board approved proposed acquisitions of 60% stakes in Saicriti Pharma for Rs 83.8 Cr and Prathyak Laboratories for Rs 15 Cr, subject to shareholder approval; approved IPO-proceeds reallocation, a US step-down subsidiary and related-party transactions. Company Secretary and a non-executive director resigned.